抑制SYK或BTK增强SHP1阴性/BCL-2阳性弥漫大B细胞淋巴瘤对维奈克拉的敏感性
在BCL-2阳性DLBCL细胞系及异种移植模型中,药理学抑制SYK或BTK可协同增强维奈克拉的敏感性,尽管直接细胞毒作用有限。该增敏效应与下游PI3K/AKT通路抑制及MCL-1、BIM和HRK表达变化相关。BCR依赖性GCB DLBCL细胞中SHP1磷酸酶缺陷,重新表达SHP1可减少SYK、BLNK和GSK3磷酸化并诱导相应表达变化。
要点
- 抑制SYK或BTK可协同增强BCL-2阳性DLBCL对维奈克拉的敏感性。
- 增敏效应与PI3K/AKT通路抑制及MCL-1、BIM、HRK表达变化相关。
- SHP1缺陷可能是GCB DLBCL中BCR通路组成性激活的原因。
核心结论
- SHP1缺陷可能是GCB DLBCL中BCR通路组成性激活的原因。
- SHP1和BCL-2可能是维奈克拉/BCR抑制剂联合治疗反应的潜在预测标志物。
研究设计与样本
- 研究使用BCL-2阳性DLBCL细胞系进行体外实验,并在异种移植模型中进行体内实验。
主要发现
- 药理学抑制SYK或BTK在体外和体内异种移植模型中协同增强维奈克拉敏感性,尽管直接细胞毒作用仅中等。
- 增敏效应与下游PI3K/AKT通路抑制及MCL-1、BIM和HRK表达变化相关。
- BCR依赖性GCB DLBCL细胞以磷酸酶SHP1缺陷为特征,SHP1是BCR通路的关键负调控因子。
- 在GCB DLBCL细胞中重新表达SHP1可减少SYK、BLNK和GSK3磷酸化,并诱导MCL1、BIM和HRK表达相应变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting SYK or BTK will increase sensitivity of DLBCL cells to venetoclax. We report that pharmacological inhibition of SYK or BTK synergistically enhances venetoclax sensitivity in BCL-2-positive DLBCL cell lines with an activated BCR pathway in vitro and in a xenograft model in vivo, despite the only modest direct cytotoxic effect. We further show that these sensitizing effects are associated with inhibition of the downstream PI3K/AKT pathway and changes in the expression of MCL-1, BIM, and HRK. In addition, we show that BCR-dependent GCB DLBCL cells are characterized by deficiency of the phosphatase SHP1, a key negative regulator of the BCR pathway. Re-expression of SHP1 in GCB DBLCL cells reduces SYK, BLNK, and GSK3 phosphorylation and induces corresponding changes in MCL1, BIM, and HRK expression. Together, these findings suggest that SHP1 deficiency is responsible for the constitutive activation of the BCR pathway in GCB DLBCL and identify SHP1 and BCL-2 as potential predictive markers for response to treatment with a venetoclax/BCR inhibitor combination.
引用
- Sasi BK, Martines C, Xerxa E, et al. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia. 2019. PMID: 30872780. doi:10.1038/s41375-019-0442-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。